Nav: Home

Gene variant explains racial disparities in adverse reactions to urate-lowering drug

April 13, 2016

A multi-institutional study led by a Massachusetts General Hospital (MGH) investigator finds significant racial disparities in the risk that patients being treated for gout will develop a serious, sometimes life-threatening adverse reaction to the most commonly prescribed medication. The increased risk closely correlates with the frequency of a gene variant previously associated with that adverse reaction, supporting recommendations to screen for that variant in patients from those populations.

"We found that Asian and black patients have a substantially higher risk of severe cutaneous adverse reactions to urate-lowering drugs than do white or Hispanic patients, which correlates with the frequency of the HLA-B*5801 gene in their U.S. populations," says Hyon K. Choi, MD, DrPH, of the MGH Division of Rheumatology, Allergy and Immunology, senior author of the report that has been published online in Seminars in Arthritis and Rheumatism. "This risk is almost certainly due to allopurinol, the dominant urate-lowering drug in the U.S., and screening gout patients from those populations for the HLA-B*5801 variant could help increase treatment safety."

Caused by excessive levels of uric acid in the body, gout involves the deposition of uric acid crystals in the joints, leading to inflammation and significant pain. Treatment can involve dietary changes - including reduced protein intake and alcohol consumption - anti-inflammatory and pain-relieving drugs, as well as urate-lowering medications. More than 95 percent of U.S. prescriptions for such drugs are for allopurinol.

Severe cutaneous reactions to allopurinol - which are called toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) - are rare, but can be extremely serious. In TEN, overwhelming inflammation causes the outer layer of skin to separate from the underlying layers, leaving the body open to severe infections. SJS/TEN can be fatal more than 30 percent of the time and may involve other major organs, potentially leaving survivors with long-term damage to the kidneys or eyes.

Studies have associated the HLA-B*5801 variant with the risk of these reactions in particular Asian populations - Koreans, Japanese, Thai and Han Chinese - and in some Europeans; and the current study was designed to investigate whether the frequency of the HLA-B*5801 variant across races leads to significant racial disparities in the risk of severe cutaneous reactions to urate-lowering drugs in a representative U.S. population. The researchers examined data covering 2009 to 2013 from the Nationwide Inpatient Sample of the Agency for Healthcare Research and Quality.

From that database of between 5 and 8 million hospitalizations each year, they identified 606 with a principal diagnosis of SJS/TEN related to an adverse reaction to urate-lowering drugs. While the database does not include information on specific medications, the frequency with which allopurinol is prescribed implies that most, if not all, of those reactions involved that drug, the authors note.

Among patients with that diagnosis, there was a significant over-representation of Asian and black patients compared with whites. For example, while another database indicates that Asian patients represented only 2 percent of U.S. allopurinol users in 2011-12, they represented 27 percent of those hospitalized for SJS/TEN related to urate-lowering drugs. Black patients represented 13 percent of allopurinol users and 26 percent of hospitalizations, while white patients represented 81 percent of allopurinol users but only 29 percent of hospitalizations. The number of Hispanic patients in the hospitalization database with this diagnosis was extremely small.

Overall the risk of these dangerous reactions was 12 times higher for Asian patients and 5 times higher for black patients compared with white patients. Those differences are closely aligned with the frequency of the HLA-B*5801 variant in those populations - a 7.4 percent frequency in Asians, 4 percent in blacks, and 1 percent in both whites and Hispanics.

"Since no other urate-lowering drug is an established cause for these severe adverse reactions, our findings support the use of vigilance when considering allopurinol for Asian and black patients with gout," says Choi, who is a professor of Medicine at Harvard Medical School. "Right now, we recommend testing for the HLA-B*5801 variant among those patients, and further research may help to identify additional factors that can improve risk management. It should also be noted that our findings apply almost exclusively to patients who are starting allopurinol, since nearly all of these severe adverse events occur during the first three to six months of treatment. Patients who have been tolerating allopurinol after the initial few months almost certainly do not have to worry about these reactions."
-end-
The lead author of the Seminars in Arthritis and Rheumatism report is Na Lu, MPH, of the Boston University School of Medicine. Additional co-authors are Sharan K. Rai, Arthritis Research Canada; Robert Terkeltaub, MD, University of California at San Diego; Seoyoung Kim, MD, ScD, Brigham and Women's Hospital; and Mariano E. Menendez, MD, MGH Department of Orthopaedic Surgery. The study was supported in part by National Institutes of Health grant R01-AR065944.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $800 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine. In July 2015, MGH returned into the number one spot on the 2015-16 U.S. News & World Report list of "America's Best Hospitals."

Massachusetts General Hospital

Related Gout Articles:

New study reveals new drug target for gout and other inflammatory diseases
Particle-driven diseases sound exotic and include things like silicosis and asbestos, but actually also include much more common diseases like Alzheimer's, gout and even atherosclerosis.
Gout hospitalization exacerbated by failure to prescribe recommended urate-lowering treatment
The results of a Swedish study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 revealed an increasing incidence of hospitalization due to gout over the last decade, with a resultant increase in health care costs.
Drug combination benefits patients with tophaceous gout
The drug lesinurad in combination with febuxostat was better at lowering blood levels of urate than febuxostat alone in a phase III clinical trial of 324 patients with tophaceous gout.
Anti-hypertension DASH diet may reduce the risk of gout
The results of a study led by Massachusetts General Hospital investigators suggest that following a diet known to reduce the risk of hypertension and cardiovascular disease may also reduce the risk of gout.
Diet rich in fruit, vegetables and whole grains may lower risk of gout
A diet rich in fruit and vegetables, nuts and whole grains and low in salt, sugary drinks, and red and processed meats, is associated with a lower risk of gout, whereas a typical 'Western' diet is associated with a higher risk of gout, finds a study published by The BMJ today.
Could a ketogenic diet alleviate gout?
Recent work from the laboratory of Vishwa Deep Dixit, Professor of Comparative Medicine and Immunobiology, has shown that the ketone body β-hydroxybutyrate can specifically inhibit the NLRP3 inflammasome.
High fiber diets may alleviate inflammation caused by gout
New research published in the Journal of Leukocyte Biology, shows that a high-fiber diet likely inhibits gout-related inflammation caused by monosodium urate (MSU) crystals.
Hyperuricemia is associated with musculoskeletal pain
Episodes of diffuse musculoskeletal pain appearing in and around a joint region without a clear diagnosis, etiology and therapy are still a major problem in general medical practice.
Allopurinol does not increase chronic kidney disease risk in gout patients
Allopurinol, a widely used treatment for lowering serum urate levels, does not appear to increase risk of kidney deterioration in gout patients with normal or near-normal kidney function, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Urate-lowering therapy helps chronic kidney disease patients improve organ function
Chronic kidney disease patients who take urate-lowering therapy and achieve target urate levels show improvement in kidney function, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.

Related Gout Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Don't Fear Math
Why do many of us hate, even fear math? Why are we convinced we're bad at it? This hour, TED speakers explore the myths we tell ourselves and how changing our approach can unlock the beauty of math. Guests include budgeting specialist Phylecia Jones, mathematician and educator Dan Finkel, math teacher Eddie Woo, educator Masha Gershman, and radio personality and eternal math nerd Adam Spencer.
Now Playing: Science for the People

#517 Life in Plastic, Not Fantastic
Our modern lives run on plastic. It's in the computers and phones we use. It's in our clothing, it wraps our food. It surrounds us every day, and when we throw it out, it's devastating for the environment. This week we air a live show we recorded at the 2019 Advancement of Science meeting in Washington, D.C., where Bethany Brookshire sat down with three plastics researchers - Christina Simkanin, Chelsea Rochman, and Jennifer Provencher - and a live audience to discuss plastics in our oceans. Where they are, where they are going, and what they carry with them. Related links:...